Heartbeam (BEAT) investor relations material

Executive summary

• Advanced heart attack detection initiatives with clinical validation ahead of schedule, including completed enrollment in the ALIGN-ACS pilot study and over 50% enrollment in the HEADSTART-ACS study in Indonesia; FDA pre-submission completed for a new indication.

• Initial commercial launch underway, targeting concierge practices and integrated network partnerships, with positive feedback from physicians and patients, multiple agreements signed across four U.S. regions, and first orders shipped.

• Proprietary TriCor 3D signal reconstruction technology embedded in multiple form factors, including a new 12-lead ECG patch prototype, addressing post-discharge, in-hospital, and remote monitoring needs.

• Strong intellectual property position with 25+ issued patents worldwide, including new patents for acoustic sensing and fluid monitoring.

• Strategic operational realignment and leadership changes implemented, with the founder assuming principal executive officer duties.

Financial highlights

• Net cash used in operating activities was $3.3 million for Q2 2026, a 7% decrease from Q1 2026 and a 3% decrease year-over-year.

• Net loss for Q2 2026 was $5.0 million, or $(0.10) per share, including one-time items related to leadership transition; underlying net loss would have been $4.1 million, down 12% sequentially and 17% year-over-year.

• Cash, cash equivalents, and restricted cash totaled $8.8 million at June 30, 2026, up from $4.4 million at year-end 2025.

• Operating expenses for Q2 2026 were $5.1 million, with SG&A at $2.8 million and R&D at $2.3 million.

• April 2026 capital raise brought in $11.5 million, extending cash runway into 2027.

Outlook and guidance

• Expectation to begin pivotal heart attack detection trial before year-end, pending FDA feedback.

• Commercial rollout in concierge practices expected to accelerate through 2027, with break-even projected at fewer than 30,000 patients.

• Q3 2026 cash outflow expected to be in line with Q2, with Q4 baseline operating cash outflow projected below $2.5 million; full-year outflows projected under $14 million.

• Cash receipts from commercial launch expected to partially offset trial-related spending in the second half of 2026.

• Cash runway extended into 2027, supporting continued execution of strategic priorities.